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Abstract 
 
Elevated plasma arginine vasopressin (AVP) levels have been found in 
human hypertension subjects and several salt dependent experimental animal 
models of hypertension including the Dahl salt sensitive hypertension (SSHTN) 
model. The orexin system is involved in AVP regulation and its over activation 
has been implicated in hypertension, however, the role of brain orexin in 
SSHTN is unknown. We hypothesized that increased activity of orexin in the 
paraventricular nucleus (PVN), a prominent region in AVP production, 
contributes to SSHTN via enhancing AVP signaling. Eight-week-old male adult 
Dahl salt sensitive (DS) and age and sex matched Sprague Dawley (SD) rats 
were placed on either a high salt (HS, 8% NaCl) or normal salt (NS, 0.4% NaCl) 
diet for 5 weeks. Five weeks HS intake did not increase mean arterial pressure 
(MAP) or alter PVN mRNA expression of chronic neuronal activation marker 
Fra1, orexin receptor 1 (OX1R), or orexin receptor 2 (OX2R) but increased 
PVN AVP mRNA expression in SD rats. HS diet induced significant increases 
in MAP and PVN mRNA levels of Fra1, AVP, OX1R, and prepro orexin in DS 
rats. Intracerebroventricular (ICV) infusion of orexin A (0.2 nmol) increased 
PVN AVP mRNA levels in SD rats. Incubation of cultured hypothalamus 
neurons from newborn SD rats with orexin A resulted in increases in AVP 
mRNA expression which were attenuated by OX1R blockade. In addition 
increased cerebrospinal fluid (CSF) sodium concentration through ICV infusion 
of NaCl salt solution (4µmol) increased PVN OX1R and AVP mRNA levels in 
SD rats. Furthermore, bilateral PVN microinjection of the OX1R antagonist 
SB408124 resulted in a greater reduction in MAP in HS intake (-16±5 mmHg) 
compared to NS fed (-4±4 mmHg) anesthetized DS rats. These results suggest 
that elevated PVN OX1R activation may be involved in SSHTN through 
enhancing AVP signaling. 
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Chapter 1. Introduction 
1.1 Overview and Significance 
High blood pressure or hypertension is highly prevalent (102) and 
contributes significantly to both the incidence and mortality from cardiovascular 
disease in particular ischemic heart disease and stroke (80). Since 
cardiovascular disease is the leading global cause of death responsible for 
more than 17 million deaths per year (102) the discovery of the causes of 
hypertension are of great importance to society. It is well-established that 
elevated salt intake is a primary contributor to essential hypertension (74, 108, 
148, 149) and the majority of individuals with essential hypertension are salt 
sensitive (148) meaning increased salt intake will increase blood pressure and 
decreased salt intake will decrease blood pressure in these individuals. 
Abnormalities in renal, vascular, hormonal, and neural responses to salt 
contribute to the pathogenesis of salt sensitive hypertension (SSHTN) (74). 
However, the cellular and molecular mechanisms that link elevated salt intake 
and hypertension are not fully understood. Therefore, the discovery of new 
mechanisms whereby salt contributes to hypertension may elucidate new 
targets for future treatment.  
1.2 Regulation of Arterial Blood Pressure 
As the blood is pumped by the heart it exerts a force over a unit surface 
area on the blood vessel walls that is termed blood pressure. With every single 
heartbeat, pressure on the vessel walls oscillates from a high pressure when 
the ventricles contract termed the systole portion of the heart cycle to a lower 
pressure when the ventricles relax and refill termed the diastole portion of the 
heart cycle. Therefore, when measured, usually at the brachial artery, blood 
pressure is given as two numbers, the pressure at systole over the pressure at 
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diastole. At any point in time during a single heart cycle the pressure will be 
somewhere in this range between the systole and diastole pressures. For 
adult’s blood pressure should normally be <120/80 mmHg (14). Due to the 
pumping action of the heart, a pressure difference between the arteries and 
veins is created with pressure that is highest in the arteries and lowest in the 
veins. This pressure difference causes blood to flow in the circulation (92). 
Using the fundamental equation equivalent to Ohm’s law for circuits that relates 
flow to resistance and pressure (∆Pressure=flow x resistance), and assuming 
pressure at the end of venous system to be negligible, then the mean pressure 
of the arterial side (MAP) of the systemic circulatory system can be calculated 
by the product of cardiac output (CO) and total peripheral resistance (TPR) 
(MAP=CO X TPR) (92). CO is further defined as the product of stroke volume 
(SV) and heart rate (HR) (CO=SV X HR) (118). Arterial blood pressure is 
regulated by two main systems, the kidneys regulation of blood volume and the 
autonomic nervous system control over the kidneys, heart, and vasculature.  
1.2.1 Short Term Blood Pressure Regulation 
Acute regulation of blood pressure (minutes to hours) is regulated via the 
baroreceptor reflex control of sympathetic nerve activity (SNA) (20). 
Mechanoreceptors located in the carotid sinus and aortic arch have discharge 
frequencies that depend on arterial pressure (112). Afferent signals are sent 
from these mechanoreceptors via the carotid sinus nerve (a branch of cranial 
nerve IX; glossopharyngeal) and aortic depressor nerve (a branch of cranial 
nerve X; vagus) to the nucleus tractus solitarii (NTS) in the medulla (114, 136). 
The NTS has excitatory projections to the caudal ventrolateral medulla (CVLM) 
(117) and the CVLM has inhibitory projections to the rostral ventrolateral 
medulla (RVLM) (114) which is the main nuclei responsible for tonic excitatory 
drive to sympathetic preganglionic neurons in the intermediolateral cell column 
(IML) of the spinal cord (54). When blood pressure is reduced the discharge 
frequencies of the mechanoreceptors in the carotid sinus and aortic arch are 
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reduced and the inhibitory influence of the CVLM on the RVLM is decreased. 
This results in an increase in sympathetic stimulation to the heart resulting in an 
increase in HR and force of contraction which increases SV and thus CO, 
increased sympathetic stimulation to blood vessels to increase vascular 
resistance, and activation of renal sympathetic nerves innervating the 
juxtaglomerular cells stimulating renin secretion and Ang II formation ultimately 
resulting in elevated blood volume and CO. Collectively these actions result in a 
compensatory increase in blood pressure (48). Alternatively, when blood 
pressure is increased the inhibitory influence of the CVLM on the RVLM is 
increased resulting in a decrease in sympathetic outflow to the heart, 
vasculature, and kidneys to decrease blood pressure (48) (Figure 1.1). 
 
 
Figure 1.1 Diagram of the arterial baroreceptor reflex control of short term 
blood pressure regulation. Solid lines, excitatory; dashed line, inhibitory. (NTS) 
nucleus tractus solitarii, (CVLM) caudal ventrolateral medulla, (RVLM) rostral 
ventral lateral medulla, (SGN) sympathetic ganglionic neuron. Adapted from 
Brooks and Osborn (9). 
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1.2.2 Long Term Blood Pressure Regulation 
Long term (weeks to months) regulation of arterial pressure is 
predominately regulated by the kidneys (57). The kidneys have the intrinsic 
ability to excrete salt (natriuresis) and water (diuresis) in response to increased 
perfusion pressure. Long term arterial pressure is set by the kidneys at a level 
that is required to excrete a volume of water or amount of salt equivalent to 
water or salt intake or in order to maintain sodium and water balance over an 
extended period of time (56). If salt intake or water intake is greater than 
excretion, extracellular fluid volume will increase which will increase blood 
volume leading to an increase in cardiac output and increase arterial pressure. 
In response to the increased pressure the kidneys will increase excretion of 
salt/water to reduce extracellular fluid volume and ultimately arterial pressure 
back to the equilibrium pressure were salt and water intake is equivalent to salt 
and water excretion. If salt or water intake is less than excretion, arterial 
pressure decreases and the kidneys decrease natriuresis /diuresis until arterial 
pressure returns to the equilibrium pressure (55, 56) (Figure 1.2).  
 
Figure 1.2 Diagram of the kidneys control of long term blood pressure 
regulation. (BP) blood pressure, (ECF) extracellular fluid. 
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1.3 Body Fluid Homeostasis and Vasopressin  
Body water is separated into two compartments; the extracellular fluid 
(ECF) (which is comprised of interstitial fluid and plasma or intravascular fluid) 
and intracellular fluid (ICF) (3). Dissolved in the body fluids are many different 
salts including NaCl, KCl, and NaHCO3. Out of these NaCl is consumed in 
greatest amounts and the cation Na+ is the major component of extracellular 
fluid (3). Therefore, its quantity largely determines extracellular osmolality (the 
concentration of all dissolved solutes in a solution) which determines 
extracellular and intracellular fluid volume (143). Changes in salt intake thus 
pose a common daily challenge to the maintenance of body fluid homeostasis 
(maintaining osmolality of body fluids and intravascular blood volume).  
When NaCl is ingested its ion components Na+ and Cl- are absorbed in 
the small intestine and become evenly distributed in the plasma of the blood. 
This results in an increase in ECF osmolality (143). Since sodium ions do not 
easily cross the cell membrane they are confined to the ECF compartment. 
However, water can cross the cell membrane and moves from a region of low 
osmolality to high osmolality. Therefore, when sodium ions accumulate in the 
ECF compartment water moves from the ICF compartment (low osmolality) to 
the ECF compartment (high osmolality) were the fluid volume expands above 
normal volume (143). Several physiological responses are then initiated to 
restore sodium and water balance including increased thirst and release of 
arginine vasopressin (AVP) the antidiuretic hormone which increases renal 
reabsorption of water (3). Both compensatory responses dilute the extracellular 
Na+ concentration back to normal. Natriuresis via the kidneys, is also increased 
and the excess salt is eliminated in the urine and the ECF fluid volume naturally 
returns to normal (3).  
If sodium concentration in the extracellular compartment is reduced ECF 
osmolality is reduced and water moves from the ECF compartment (low 
osmolality) to the ECF compartment (high osmolality) were fluid volume 
expands above normal (3). This results in a decrease of circulating sodium 
concentration and reduced blood pressure. The kidneys increase the release of 
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renin which catalyzes the formation of angiotensin I from angiotensinogen. The 
angiotensin converting enzyme catalyzes the reaction of angiotensin I to 
angiotensin II. Angiotensin II causes vasoconstriction in order to increase blood 
pressure and also stimulates the secretion of aldosterone from the adrenal 
gland. Aldosterone causes sodium reabsorption by the kidneys in order to 
prevent its loss in the urine (3). It has also been shown in animals that thirst 
along with AVP secretion are also responses to sodium depletion (17, 63) 
which supports that thirst and AVP secretion are additionally regulated by 
volume dependent mechanisms.   
1.3.1 Neural Circuitry Involved in Osmotic Regulation of Vasopressin 
Release 
AVP secretion is predominantly regulated by changes in blood osmolality 
and to a lesser extent by a decrease in ECF volume (43). In particular E.B. 
Verney was the first to show that only hypertonic solutions with solutes such as 
NaCl that are impermeable to the cell membrane and create osmotic pressure 
activate osmoreceptors that trigger thirst and AVP release (145). In this early 
study E.B. Verney concluded these osmoreceptors responsible for the 
regulation of AVP secretion were located in the brain. In a further study by 
Jewell et al. the location was narrowed down to be in the anterior hypothalamic 
area (67). It was latter suggested by two groups (95, 139) that these 
osmoreceptors likely lied outside of the blood brain barrier since carotid artery 
infusion of hyperosmolar solutions of NaCl, sucrose, or urea which do not pass 
the blood brain barrier effectively withdrew water and dehydrated the brain 
compartment however only hyperosmolar solutions of NaCl and sucrose which 
do not easily cross the cell membrane stimulated AVP release and thirst. Since 
urea easily penetrates the cell membrane it likely did not dehydrate and 
activate the supposed osmoreceptors that were present outside the blood brain 
barrier (95). Mckinley hypothesized the location of these osmoreceptors to be 
the two circumventricular organs of the lamina terminalis region which is 
located on the rostral wall of the 3rd ventricle that lack a blood brain barrier (95, 
96). These circumventricular organs are called the organum vasculosum of the 
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lamina terminalis (OVLT) and the subfornical organ (SFO). 
 Most neurons in the brain are protected from changes in concentrations 
of circulating ions and hormones in the plasma that organs and tissues are 
usually exposed to by the presence of blood brain barrier that limits exchange 
between plasma in brain blood capillaries and brain tissue. However, the SFO 
and OVLT have a highly penetrable blood brain barrier due to fenestrated 
capillaries therefore they are sensitive to changes in plasma osmolality and 
circulating hormones (19). Another region of the lamina terminalis called the 
median preoptic nucleus (MnPO) lies between the OVLT and SFO. Both the 
SFO (82, 98) and OVLT (93) have direct excitatory projections to the 
hypothalamic paraventricular nucleus (PVN) as well as indirect excitatory 
projections to the PVN through projections to the MnPO (82, 98). The PVN is 
composed of parvocellular and magnocellular neurons. Parvocellular neurons 
have axon projections to the RVLM in the brainstem and IML in the spinal cord 
which play significant roles in regulating SNA (13, 116). Magnocellular PVN 
neurons synthesize AVP and transport it along nerve fibers that connect the 
hypothalamus with the posterior lobe of the pituitary gland called the 
neurohypophysis were it is stored and released (115).  
The function of these circumventricular organs in the regulation of AVP 
secretion has been supported by lesion studies. Separate lesions of the OVLT 
and SFO and MNPO all attenuate osmotic stimulation of AVP release (86, 87, 
94, 140). Total ablation of the lamina terminalis completely abolished osmotic 
stimulation of AVP (96) demonstrating all three regions may be important in 
osmotic stimulation of AVP release. In addition to these circumventricular 
organs as the brain site for osmotic regulation of AVP release, evidence 
suggests these regions are also responsible for angiontensin II regulation of 
AVP release. Cutting SFO efferents was found to attenuate angiotensin II 
induced stimulation of AVP release (73). It has also been shown that this region 
displays high density of the angiotensin II type 1 receptor (97).  
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1.3.2 Vasopressin Hemodynamics and Blood Pressure Control 
Mechanisms  
In addition to the role of AVP in body fluid homeostasis, AVP is involved 
in blood pressure regulation. In normal conscious rats, dogs, and humans it has 
been found that acute 30-60 minute intravenous infusions of AVP exerts a 
significant dose dependent increase in MAP only at non physiological high 
plasma concentrations that are higher than those required for antidiuresis (26). 
However, it has also been found in rats, dogs, and humans that plasma AVP 
exerts vasoconstrictor activity at lower physiological concentrations within the 
range of maximum antidiuretic activity (26). The lack of a pressor response to 
increased plasma AVP levels at lower physiological concentrations is due to its 
action of decreasing cardiac output as acute 30-60 min Intravenous infusion of 
AVP exerts a dose dependent decrease in cardiac output in rats, dogs, and 
humans (26).  
The ability of AVP to decrease cardiac output and buffer the pressor 
response may be explained by AVP activating reflex decreases in SNA. It has 
been shown that animals that have received baroreceptor denervation or where 
the central nervous system was totally eliminated develop an increased blood 
pressure response at lower amounts of intravenously administered AVP (22, 26, 
110, 147). This enhancement of pressor sensitivity is greater than other 
vasoconstrictor agents such as angiotensin II or norepinephrine (22, 26, 110, 
147) which demonstrates AVP is one of the most powerful circulating 
vasoconstrictors. One mechanism is the ability of circulating AVP to activate V1 
receptors in the area postrema, which is another circumventricular organ 
lacking a blood brain barrier, and augment baroreflex sympatho-inhibition (60). 
Microinjection of AVP into the SFO decreased mean area under the curve 
blood pressure but not heart rate in SD rats which was blocked by V1 receptor 
blockade suggesting AVP may also activate V1 receptors in the SFO outside of 
the baroreflex neural circuitry resulting in a decrease in SNA (135).  
The known mechanisms that circulating AVP can increase blood 
pressure include activation of V1A Gq/11 protein coupled receptors on vascular 
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smooth muscle cells causing contraction, inducing vasoconstriction and 
increasing total peripheral resistance. The widely accepted calcium signaling 
pathway for the V1A receptor on vascular smooth muscle cells involves 
phospholipase C activation of IP3 (8, 106).  When activated the alpha subunit 
of the Gq/11 protein exchanges GDP for GTP and dissociates from the beta and 
gamma subunits. The GTP bound alpha subunit binds and activates 
phospholipase Cβ which causes the hydrolysis of P1P2 increasing levels of 
DAG and IP3. IP3 binds the IP3R on the endoplasmic reticulum and stimulates 
calcium release into the cell (8, 106) which causes contraction of the cell 
(Figure 1.3). AVP may also act on the kidneys to increase water reabsorption 
causing an increase in intravascular volume which will increase SV and 
ultimately arterial pressure. This is mediated through activation of V2 Gs protein 
coupled receptors on the basolateral membrane of the principle cells of the 
kidney collecting duct (8). When activated the alpha subunit of the Gs protein 
exchanges GDP for GTP and dissociates from the beta and gamma subunits. 
The GTP bound alpha subunit binds and activates adenylate cyclase which 
takes ATP and produces the second messenger cAMP. cAMP activates protein 
kinase A which increases exocytosis and decreases endocytosis of aquaporin 
water channel containing vesicles. This increases aquaporin 2 channels in the 
apical membrane and allows water to leave the collecting duct and enter the 
renal collecting duct cell where it eventually enters the blood (8) (Figure 1.3).  
10 
 
 
 
Figure 1.3 (left) Diagram of intracellular mechanism for vasopressin (AVP) 
binding V2R (V2 Receptor) on basolateral membrane of a kidney collecting duct 
cell increasing water reabsorption from the collecting duct which eventually 
enters the bloodstream increasing arterial blood pressure. (Right) Diagram of 
intracellular mechanism for AVP binding V1aR (V1a receptor) on vascular 
smooth muscle cell increasing intracellular calcium and contraction leading to 
increased vascular resistance and arterial blood pressure. Abbreviations: 
(GDP) guanosine diphosphate, (GTP) guanosine triphosphate, (ATP) 
adenosine triphosphate, (cAMP) cyclic adenosine monophosphate, (AC) 
adenylyl cyclase, (PKA) protein kinase A, (AQP-2) aquaporin, (PLCβ) 
phospholipase Cβ, (PIP2) phosphatidylinositol (4,5)-bisphosphate, (DAG) 
diacylglycerol, (IP3) inositol (1,4,5)-triphosphate, (IP3R) inositol (1,4,5)-
triphosphate receptor, (ER) endoplasmic reticulum, (MAP) mean arterial 
pressure, (TPR) total peripheral resistance, (CO) cardiac output. Adapted from 
Birnbaumer et al. (8).   
 
1.4 Salt Sensitive Hypertension  
The blood pressure values that define hypertension are a systolic blood 
pressure >140 mmHg or a diastolic blood pressure > 90 mmHg (14). 
Hypertension can be classified based on etiology. If the cause is not known it is 
termed essential or primary hypertension which accounts for most cases of 
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hypertension (10). Essential hypertension has the potential to be caused by a 
wide range of factors because blood pressure is influenced by genetics, 
behavior, and the environment (10). However, salt plays a central role in 
essential hypertension since it has been shown the majority of individuals with 
essential hypertension are salt sensitive (148) which suggests hypertension in 
these individuals is largely dependent on salt intake.  
Arguably one of the most prominent figures in the discovery of the 
relationship between salt and hypertension is Dr. Lewis Dahl. Dahl was the first 
to compare salt intake and the prevalence of hypertension between several 
populations in the world. Using data from radiation research conducted by the 
United States Atomic Energy Commission after WWII, Dahl found that 
populations with higher salt consumption had a higher prevalence of 
hypertension (32). Along with Dr. Dole and Cotzias, Dahl was also the first to 
confirm in the 1950’s through human metabolic studies that the reduction in 
blood pressure from Kempner’s rice-fruit diet, that had been previously found to 
be useful for treatment of hypertension (70, 71), was due to its low sodium 
content (40-42). Dahl later hypothesized that since a low salt diet lowered blood 
pressure a high salt (HS) diet may cause an increase in blood pressure (33). 
Dahl tested this hypothesis through a series of studies using an experimental 
form of hypertension were Sprague-Dawley rats were fed a chronic HS diet 
while their blood pressure was monitored. He found that some rats had no 
blood pressure response and the rest of the rats developed varying degrees of 
elevations in blood pressure (30, 31, 34). From these experiments it was 
apparent to Dahl that genetic factors that determined susceptibility to salt were 
responsible for the variations in blood pressure responses (37). This led to 
development of the Dahl rat model of SSHTN.    
1.4.1 Dahl Salt Sensitive Hypertension Model 
In the 1960’s Dr. Lewis Dahl developed his animal model of SSHTN that 
is still one of the most widely studied models today. Dahl fed Sprague-Dawley 
(SD) rats a L-triiodothyronine-sea salt diet then selected and bred the rats that 
developed the greatest elevations in blood pressure. He also selected and bred 
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rats that had no blood pressure response to the HS diet. Through repeated diet 
treatment, selection, and inbreeding of both groups Dahl obtained entire 
statistically different populations of rats that were very sensitive (Dahl salt-
sensitive rats (DS) and the other that was very resistant called (Dahl salt 
resistant rats) to the development of HS induced hypertension (35-37). This 
ability to isolate separate populations confirmed that the variability in blood 
pressure in response to a high salt diet in the original unselected population of 
SD rats was due to genetic factors that controlled sensitivity to salt rather than 
due to statistical extremes of a homogenous population (37).  
1.4.2 Vasopressin in Hypertension and Contribution to Dahl Salt Sensitive 
Hypertension Model 
Increased osmolality naturally results from hypernatremia and activates 
osmoreceptors resulting in AVP release. Given AVP plays a role in blood 
pressure regulation, It is logical that alterations in this essential physiological 
response may therefore be a mechanism by which a HS diet can lead to the 
development or maintenance of hypertension. However, In normal rats and 
dogs long term administration of AVP to increase levels observed in 
hypertension does not produced sustained hypertension (111, 134). This has 
been demonstrated in dogs were AVP was infused for 3-4 weeks to increase 
plasma levels to those observed in hypertension where water intake was 
regulated to remain constant (134). MAP increased around 40 mmHg along 
with an increase in body weight followed by a return of MAP and body weight 
towards normal at the end of the two weeks. However, in dogs where total body 
fluid volume was servo controlled MAP or body weight did not change over a 
two-week period were the same amount of AVP was infused (21). This finding 
supports the notion that the antidiuretic actions of AVP may be more important 
than the vasoconstrictive actions of AVP in hypertension although additionally 
AVP may not sustain hypertension in normal animals because it cannot sustain 
blood volume expansion (25).  
This phenomenon where the antidiuretic actions of AVP do not last is 
called AVP escape. One mechanism of AVP escape is simply the kidneys 
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intrinsic ability of pressure diuresis in response to elevated circulating AVP 
causing blood volume expansion and elevated renal perfusion pressure since 
long term administration of a subpressor dose of AVP in dogs with only 30% of 
normal renal mass to reduce natriuresis and diuresis ability induced sustained 
hypertension for 14 days (88). Blood pressure significantly increased within 
three days of AVP administration and decreased back to normal within three 
days when administration of AVP was stopped. Other mechanisms of AVP 
escape include down regulation of V2 receptors in the inner medulla of the 
kidneys (141), decreased expression of aquaporin-2 water channel in the renal 
collecting duct (44), and Increased renal prostaglandin E2 (51). Also AVP may 
not sustain hypertension due to its opposing actions on controlling blood flow to 
the renal medulla resulting in its inability to chronically reduce renal medullary 
blood flow. V1 receptor activation presumably on the medullary vasa recta 
decreases renal medulla blood flow while V2 receptor activation increases renal 
medulla blood flow (104). In conscious rats, chronic renal interstitial infusion of 
an V1 receptor agonist significantly decreased inner medullary blood flow, 
produced no change in cortical blood flow, and significantly increased MAP. 
However chronic renal interstitial infusion of AVP which would activate V1 and 
V2 receptors did not significantly decrease inner medulla blood flow or 
significantly increase MAP (23). Evidence suggests V2 receptor activation in 
the inner medulla collecting duct cells stimulates nitric oxide production which 
may oppose V1 receptor action and increase medullary blood flow by 
vasodilation of the medullary vasa recta (107).  
Nevertheless enhanced AVP levels have been found in human 
hypertension subjects (24, 109) and several animal models of experimental 
hypertension such as spontaneously hypertensive rats (28, 99), partial 
nephrectomy-salt hypertension (77), deoxycorticosterone-salt (DOC-salt) 
hypertension (29), and renovascular hypertension (100). DS rats fed a HS diet 
have greater plasma AVP levels compared to Dahl salt resistant rats fed a HS 
diet (7, 90, 124, 146). However, the contribution of AVP to the Dahl model of 
SSHTN is still controversial, as studies involving the administration of AVP 
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antagonists to DS rats with salt induced hypertension have produced varying 
results. Acute intravenous administration of the V1a receptor antagonist (CH2)5 
VDAVP had no effect on the MAP of hypertensive DS rats fed a HS diet (90). 
Oral administration of the V1a receptor antagonist OPC-21,268 prevented any 
further increase in systolic blood pressure for the first 6 days of treatment in 
male DS rats that were placed on an 8% NaCl HS diet 10 days prior (27). 
However, this effect was transient and systolic blood pressure increased to 
levels below control rats but not significantly different at the end of 12 days with 
treatment of OPC-21,268. A More recent study showed that administration of a 
dual AVP receptor antagonist RWJ-676070 produced a transient decrease in 
MAP in hypertensive DS rats on a HS diet (53). These studies suggest AVP 
contributes to HS induced hypertension in DS rats however hypertension in this 
model is not completely dependent on AVP and other mechanisms contribute 
as well. Interestingly chronic intravenous infusion of a subpressor dose of AVP 
in DS rats significantly increased MAP after 1 day and after 14 days increased 
MAP around 18 mmHg. Brown Norway rats that received the same treatment 
did not show any change in MAP throughout the 14 days (150). This data 
demonstrates DS rats are very sensitive to AVP. It has been hypothesized by 
Gunnet et al. (53) that this enhanced sensitivity to AVP may also explain the 
transient blood pressure reduction effects by AVP receptor antagonists in HS 
fed DS rats. 
 In addition to the consequences elevated AVP levels may have on V1a 
activation leading to increased vascular resistance, elevated AVP levels could 
possibly contribute to Dahl SSHTN hypertension due to volume expansion. It 
has been demonstrated that the development of hypertension in DS rats in 
response to HS diet is volume dependent. Servo controlled prevention of blood 
volume expansion prevented the rise of MAP in DS rats in response to HS 
intake (20 mEq/ day sodium) suggesting blood volume expansion may be an 
important factor in the BP development in the Dahl model (50). This is 
consistent with the hemodynamics of DS rats on a 8% NaCl HS diet. After 4 
weeks on a 8% NaCl HS diet it has been shown hypertension is mainly 
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developed and maintained due to blood volume expansion causing increased 
CO. At 8 weeks on an 8% NaCl HS diet CO is reduced (most likely due to 
autoregulation to maintain consistent tissue flow) and hypertension is 
maintained due to increased TPR (133). However, vasopressin has not been 
directly linked to this blood volume expansion stage of hypertension in DS rats. 
Despite the lack of evidence thus far that convincingly shows AVP contributes 
the Dahl model of SSHTN, the central mechanisms that mediate enhanced 
AVP levels found in this model are not well known.  
1.5 Orexin 
The neuropeptides orexin A and orexin B (also known as hypocretin 1 
and hypocretin 2) were first discovered independently in 1998 by two different 
groups. Sakurai et al. identified two neuropeptides isolated from rat brain tissue 
that were produced from the same precursor polypeptide by proteolytic 
processing (120). They found that both peptides were ligands of two closely 
related G protein-coupled receptors that had no previously known ligands. 
When centrally administered in rats, both peptides stimulated increased food 
consumption and the precursor polypetide mRNA was upregulated in 48 hour 
fasted rats. Therefore, they called these peptide ligands orexins (orexin A and 
orexin B) similar to the greek word orexis meaning appetite, and the G protein-
coupled receptors they activated orexin receptor 1 (OX1R) and orexin receptor 
2 (OX2R). They termed the precursor polypeptide prepro-orexin and the 
messenger mRNA that encoded it prepro-orexin mRNA (120). Sakurai et al. 
was the first to describe in detail the structure of the orexins produced from 
prepro-orexin polypeptide. Orexin A is a 33 amino acid peptide with two 
intrachain disulfide bonds while orexin B is a linear 28 amino acid peptide (120). 
They also found that orexin A and orexin B bind OX2R with equal affinity while 
orexin A binds to the OX1R with a higher affinity than orexin B (120). 
Independently de Lecea et al. identified the mRNA for the same 
precursor peptide and predicted this peptide was cleaved to form a pair of 
peptides (39). They called these peptides hypocretin 1 and hypocretin 2 
because their amino acid sequence was similar to members of the hormone 
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family the incretins and because they found the messenger mRNA and 
precursor polypeptide to be located in cell bodies of neurons in the 
hypothalamus (39).  
Soon after the discovery of orexin subsequent major 
immunohistochemistry studies examined where orexin producing neurons were 
localized in the brain and the regions of the brain that these neurons projected 
to. The cell bodies of neurons containing orexins were found to be exclusively 
localized only in the hypothalamus particularly in the lateral hypothalamic area, 
perifornical nucleus, dorsomedial hypothalamic nucleus, dorsal hypothalamic 
area, and posterior hypothalamic area (38, 105, 113) in the rat brain. However, 
these orexin containing neurons have widespread projections throughout the 
entire brain including the cerebral cortex, thalamus, circumventricular organs, 
limbic system, and brainstem as well as throughout the hypothalamus (38, 105, 
113). Consistent with this extensive projection throughout the brain orexin A 
and orexin B are reported to function as excitatory neurotransmitters (39, 72, 
138) and regulate numerous physiological processes including sleep and 
arousal (11, 138), feeding behavior (45, 61, 66, 120), emotion (68, 76), reward 
(59), and energy homeostasis (101) processes. Accumulation of studies now 
suggest the orexin system serves an overall function of receiving internal and 
external environment information and serves to regulate arousal and autonomic 
function to support motivated behaviors (119).  
1.5.1 Orexin Control of Cardiovascular Function 
Studies suggest one of the autonomic functions the orexin system 
regulates is the central nervous system control of cardiovascular function. 
Prepro-orexin knockout mice exhibit a lower basal arterial pressure in both 
anesthetized and conscious conditions (69). Also rats with genetic ablation of 
orexin neurons have lower systolic and diastolic pressure in both sleep and 
wake states (123). Central administration of orexin A and orexin B increases 
HR, MAP, and SNA in conscious (84, 91, 121, 129, 131) and anesthetized 
animals (4, 12, 125, 126) indicating one mechanism orexin A regulates 
circulation and blood pressure is through regulating SNA. The orexin system 
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has also been implicated in AVP regulation. ICV administration of orexin A 
increases AVP mRNA in parvocellular neurons of the PVN in conscious rats (1) 
and also plasma AVP levels in conscious rabbits (91). These findings are 
consistent with orexin containing nerve terminals (6, 15, 16, 105, 113, 126, 151) 
and receptors from in-situ hybridization studies (83, 89, 144) and 
immunohistochemistry studies (5, 18, 62) residing in many cardiovascular 
control regions of the brain including both magnocellular and parvocellular 
neurons of the PVN. Studies focusing on the action of orexin in the PVN have 
shown that orexin-A has excitatory actions by depolarizing both magnocellular 
and parvocellular neurons (47, 122, 130). The actions of orexin-A on 
magnocellular and parvocellular PVN neurons based on current evidence are 
shown in figure 1.4.  
 
Figure 1.4 Orexin-A depolarizes magnocellular and parvocellular 
paraventricular nucleus (PVN) neurons. Orexin-A may activate either glutamate 
containing presynaptic or interneurons increasing glutamate release to 
magnocellular PVN neurons activating postsynaptic glutamate receptors 
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(GlutR). Orexin-A may also enhance postsynaptic glutamate receptor function 
in magnocellular PVN neurons. Orexin-A depolarizes parvocellular PVN 
neurons through activation of non-selective cation channels (NSCC). 
Abbreviations: orexin receptor 1 (OX1R), orexin receptor 2 (OX2R). Figure 
based on data from Follwell and Ferguson (47).  
 
1.5.2 Orexin System Contributes to Hypertension 
Accumulating evidence indicates that hyperactivity of the orexin system 
contributes to several animal models of hypertension. Oral administration of the 
dual orexin receptor antagonist almorexant significantly decreased systolic 
blood pressure, diastolic blood pressure, MAP, and HR compared to pre 
treatment in conscious spontaneously hypertensive rats in both wakefulness 
and sleep during dark and light periods of the diurnal cycle (81). However, the 
same dose of the dual orexin receptor antagonist did not affect blood pressure 
or HR in Wistar Kyoto rats (81). This study suggests that over activation of the 
orexin system contributes to the maintenance of hypertension in the SHR 
hypertension model. Furthermore, ICV administration of an OX2R antibody or 
antagonist and RVLM injection of an OX2R antagonist results in a significant 
reduction in MAP and HR in spontaneously hypertensive rats but not in Wistar 
Kyoto rats (78). This study suggests that elevated OX2R activity in the RVLM 
contributes to hypertension in the spontaneously hypertensive rat model.  
The orexin system has also recently been implicated in the obese 
Zucker rat model of obesity-related hypertension. Microinjection of the OX1R 
antagonist SB334867 into the PVN significantly decreased MAP and renal 
sympathetic nerve activity (RSNA) in obese Zucker rats but not in lean Zucker 
rats (152). PVN OX2R blockade did not affect MAP or RSNA in obese Zucker 
rats or lean Zucker rats. PVN OX1R protein levels were significantly greater in 
15 week old obese Zucker rats compared to lean Zucker rats (152). Additionally 
orexin A induced a greater increase in firing rate of spinally projecting PVN 
neurons in obese Zucker rats compared to lean Zucker rats which was 
attenuated by OX1R antagonist SB334867 but not OX2R antagonist TCS OX2 
29 (152). This study suggests that upregulation of the OX1R contributes to 
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enhanced neuronal activity of PVN neurons and contributes to augmented SNA 
and hypertension in the obese Zucker rat model of obesity related hypertension. 
However, the role orexin plays in SSHTN is unknown.  
1.6 Summary and Hypothesis 
AVP production and release is a homeostatic response to 
hyperosmolality following salt ingestion and is involved in blood pressure 
control. It has been demonstrated that enhanced AVP levels associated with 
DS rats on a HS diet may contribute to Dahl SSHTN. However, the central 
mechanisms were HS stimulation may increase AVP levels and contribute to 
SSHTN are not well known. Based on recent evidence that increased activity of 
the brain orexin system is involved in hypertension we sought to investigate its 
involvement in SSHTN. Previous studies on the orexin systems role in 
hypertension have focused on orexin mediated changes in SNA therefore, we 
intended to focus on orexin mediated changes in AVP signaling. Taking into 
account the importance of the PVN in AVP and blood pressure control, and that 
orexin is involved in the regulation of PVN neuronal activity and AVP regulation 
we hypothesized that increased activity of the orexin system in the PVN may be 
responsible for enhanced AVP levels in HS fed DS rats.  
The link between how increased salt intake could activate the orexin 
system is unclear at the present time. There is no direct evidence that 
orexinergic neurons are osmosensitive or receive input from osmoreceptors in 
the lamina terminalis. However, it has previously been shown that prepro-orexin 
mRNA is upregulated In the hypothalamus of 48 hour water deprived rats (75) 
indicating orexin producing neurons may be sensitive to changes in osmolality. 
Additionally, the lamina terminalis has been shown to have projections to the 
lateral hypothalamus (58, 65), a region where the cell bodies of orexin 
producing neurons are found. 
 In DS rats a combination of genetic abnormalities may lead to chronic 
activation of the orexin system in the PVN in response to elevated salt intake. It 
has been demonstrated that DS rats have genetic functional abnormalities of 
the kidneys that reduced natriuresis or the ability to excrete salt (85). It has 
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been shown that in response sodium is abnormally sequestered in the CSF 
(132). Specifically, it has been shown that the CSF sodium concentration of DS 
rats increased to 6mM after 6 days on an 8% HS diet before development of 
hypertension hypertension (64). It has been previously hypothesized that CSF 
sodium concentration is increased in response to sodium retention in DS rats 
(132). Abnormal transport across the choroid plexus (2) may be responsible for 
increased CSF sodium concentration in DS rats. 
Given this evidence in DS rats, it is plausible that in response to a HS 
diet reduced ability of the kidneys to excrete salt may cause cerebrospinal fluid 
(CSF) sodium concentration to increase as hypothesized by Simchon et al. 
(132). The circumventricular organs in the lamina terminalis may sense 
increased osmolality due to elevated CSF sodium concentration which may 
subsequently activate orexin producing neurons located in the hypothalamus. 
Alternatively increased CSF sodium concentration may directly activate orexin 
producing neurons. This may result in increased orexin release to the PVN 
which could potentially increase PVN neuronal activity resulting in enhanced 
AVP secretion. Elevated plasma AVP levels may then play a role in the Dahl 
model of SSHTN through its vasoconstrictive or antidiuretic actions. In addition, 
the reduced ability of natriuresis by the kidneys of DS rats may support chronic 
activation of the orexin system and may explain why orexin producing neurons 
would not be chronically activated in SD or Dahl salt resistance rats in response 
to a high salt diet. This hypothesis is shown in figure 1.5.   
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Figure 1.5 Hypothesis for high salt (HS) induced activation of the orexin system 
in the paraventricular nucleus (PVN) leading to enhanced vasopressin (AVP) 
levels in Dahl salt sensitive rats. A HS diet may increase cerebrospinal fluid 
(CSF) fluid sodium concentration. Circumventricular organs (CVO) in the 
lamina terminalis may sense increased osmolality and activate orexin 
producing neurons. This may increase orexin release to the paraventricular 
nucleus and activate magnocellular (Ma) neurons and increase release of 
vasopressin (AVP) into the blood. Elevated blood AVP levels may contribute to 
hypertension in this model through vasoconstriction or increased water 
reabsorption. Reduced ability of natriuresis by the kidneys of Dahl salt sensitive 
rats may support chronic activation of the orexin system and may explain why 
orexin would not be chronically activated in Sprague Dawley or Dahl salt 
resistance rats in response to a high salt diet. Whether parvocellular (Pa) pre 
sympathetic neurons are activated by orexin and result in increased 
sympathetic nerve activity (SNA) contributing to hypertension in this model 
remains to be determined. (MAP) mean arterial pressure, (TPR) total peripheral 
resistance, (CO) cardiac output.   
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Chapter 2. Methods  
2.1 Animals  
All rats used in this study were purchased from Charles River 
Laboratories (Wilmington, MA). Eight-week-old male adult DS and age and sex 
matched SD rats were placed on either a normal salt (NS), 0.4% NaCl diet or 
HS 8% NaCl diet (Envigo RMS, IN, USA) for 5 weeks, and used for blood 
pressure measurement, brain mRNA measurement, and sympathetic nerve 
activity recording. Adult male SD rats (350-500 g) were used for brain 
intracerebroventricular (ICV) infusion. Cultured hypothalamic neurons were 
obtained from newborn SD rats. All animals were housed in two rats per cage 
and kept on a 12:12-h light-dark cycle in a climate-controlled room. Rat chow 
and water were provided ad libitum. All of the animal experiments followed 
protocols that were approved by the Michigan Technological University 
Institutional Animal Care and Use Committee. 
2.2 Blood Pressure Measurement  
 Prior to diet treatment eight week old male adult DS rats were 
anesthetized with isoflurane (3%) and telemetry transmitters were implanted 
into the abdominal aorta, and arterial pressure was monitored as described 
previously (128). Blood pressure in age and sex matched SD rats was 
monitored during diet treatment via volume pressure tail cuff method. 
2.3 Real-time PCR Analysis of PVN Fra1, AVP, Prepro Orexin, OX1R, 
and OX2R mRNA Expression 
Eight-week-old male adult DS rats and age and sex matched SD rats 
were placed on an either a normal salt (NS), 0.4% NaCI diet or HS 8% NaCI 
diet for 5 weeks. After diet treatment animals were euthanized, brains were 
removed and PVN tissue was punched. Punched PVN tissues were subjected 
to RNA isolation, using RNeasy plus Mini kit (Qiagen, CA, USA) following the 
manufacturer’s instructions.  
 
The material contained in this chapter is in preparation for submission to a journal. 
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Real-time PCR was performed to measure mRNA levels of Fra1, AVP, prepro 
orexin, OX1R, and OX2R using the specific primer and probe (Applied 
Biosystems, Foster City, CA) in the Step One Plus Real Time PCR System 
(Applied Biosystems). Data were normalized to GAPDH mRNA.   
2.4 Preparation of Neuronal Cultures 
 Primary neuronal cultures were made from the hypothalamus 
containing the PVN of 1-day-old SD rats as described previously (127). Briefly, 
rats were euthanized and the hypothalamus was immediately dissected and 
tissues were combined. Neurons were dissociated from each other and plated 
in poly-L-lysine culture dishes.  Neuronal cultures contained >95% neurons 
(remaining cells were primarily astroglia). The cultures were maintained for 10–
14 days before their use in experiments. 
2.5 Measurement of Orexin A Effect on AVP Expression in Cultured 
Brain Neurons  
 Primary neuronal cultures from the hypothalamus of 1-day old SD rats 
were incubated with vehicle control or differing concentrations of orexin (10nM, 
100nM, 1μM, 10μM) for 6 hours. The cells were collected, RNA was isolated, 
and real-time PCR was performed to measure mRNA levels of AVP. We then 
coincubated neuronal cultures with 1μM orexin with or without the orexin 
receptor 1 antagonist (OX1Ra) SB-408124 (100 µM) or orexin receptor 2 
antagonist (OX2Ra) TCS OX2 29 (100 µM) (Tocris Bioscience, united, 
Kingdom) for 6 hours. The mRNA level of AVP was determined by quantitative 
real-time PCR as described in the methods. Each set of experiments was 
performed using three separate culture dishes, and all cDNA samples were 
assayed in duplicate. The whole experiment was repeated three times. Data 
were normalized to GAPDH mRNA.  
2.6 Intracerebroventricular (ICV) Injections 
Adult male SD rats (350-500 g) were anesthetized with isoflurane (3% in 
O2). Body temperature was held at 37°C with a water-circulating pad. Animals 
were placed in a stereotaxic head frame, and the skull was leveled between 
bregma and lambda. A small piece of skull was removed so that a Hamilton 
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syringe could be lowered vertically into the left lateral ventricle. The stereotaxic 
coordinates for I.C.V injection into the left lateral ventricle were: 0.8–0.9 mm 
caudal to bregma; 1.4–1.8 mm lateral to midline; and 3.2–3.8 mm ventral to 
dura. Each rat received only one injection. For I.C.V injection, vehicle control 
(0.9% saline) was injected at a fixed volume of 2 μl over 2 min., orexin A 
(.2nmol) was injected at a fixed volume of 4 μl over 5 min., and hypertonic 
saline (4 µmol) was injected at a fixed volume of 2 μl over 2 min. Orexin A 
(Sigma-Aldrich, St. MO, USA) was dissolved in 0.9% saline. Drugs were 
injected into the left lateral ventricle using a UltraMicroPump3 (WPI). Three 
hours following ICV injection, rats were euthanized and brain PVN tissues were 
punched out and received real time PCR analysis for AVP mRNA expression 
as described in this section.  
2.7 Experimental Preparation for Sympathetic Nerve Activity 
Recordings  
 Animal surgery was performed following the previously described 
protocol (52). Briefly, rats were anesthetized with an intraperitoneal injection 
containing a mixture of α-chloralose (80 mg/kg) and urethane (800 mg/kg). 
Adequate depth of anesthesia was assessed before surgery by the absence of 
pedal and corneal reflexes and by failure to withdraw the hindlimb in response 
to pinching the paw. Animals were instrumented with an arterial catheter 
inserted into the aorta through a femoral artery. The catheter was connected to 
a pressure transducer to measure arterial blood pressure (ABP). Heart rate 
(HR) was obtained from the R-wave of the electrocardiogram (ECG) (lead I). A 
catheter was also placed in the left femoral vein to administer drugs. After 
tracheal cannulation, rats were paralyzed with gallamine triethiodide (25 
mg·kg−1·h−1 iv) and artificially ventilated with oxygen-enriched room air. After 
paralysis, adequate depth of anesthesia was determined by lack of pressor 
responses to noxious foot pinch. Supplemental doses of anesthesia equal to 
10% of the initial dose were given when needed. End-tidal PCO2 was 
continuously monitored and maintained within normal limits (35–40 mmHg) by 
adjusting ventilation rate (80–100 breaths/min) and/or tidal volume (2.0–3.0 ml). 
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Body temperature was held at 37°C with a water-circulating pad.  
2.8 Sympathetic Nerve Activity (SNA) Recording  
 SNA recording was performed as previously described (52, 137). With 
the use of a left flank incision, a left renal and splanchnic sympathetic nerve 
bundle was isolated from surrounding tissue and mounted on a stainless steel 
wire electrode (0.127-mm OD; A-M Systems), and covered with a silicon-based 
impression material (Coltene, Light Body) to insulate the recording from body 
fluids. The recorded signal was directed to an AC amplifier (P511; Grass 
Technologies) equipped with half-amplitude filters (band pass: 100-1,000 Hz) 
and a 60-Hz notch filter. The processed signal was rectified, integrated (10-ms 
time constant), and digitized at a frequency of 5,000 Hz using a 1401 Micro3 
analog-to-digital converter and Spike 2 software (7.04 version; Cambridge 
Electronic Design, Cambridge, UK). The background noise was determined by 
a bolus injection of hexamethonium (30 mg/kg iv), a ganglionic blocker, at the 
end of the experiment and was subtracted from all the integrated values of 
SNA.  
2.9 Paraventricular Nucleus (PVN) Injections  
 PVN injections were performed as previously described (52). Animals 
were placed in a stereotaxic head frame, and the skull was leveled between 
bregma and lambda for PVN injections. A small piece of skull was removed so 
that a single-barreled glass microinjector pipette could be lowered vertically into 
the PVN. The stereotaxic coordinates for PVN injections were the following: 
1.2–1.6 mm caudal to bregma; 0.5–0.7 mm lateral to midline; and 7.0–7.4 mm 
ventral to dura. The OX1R antagonist SB408124 (Santa Cruz Biotechnology, 
Texas, USA) was dissolved in DMSO. SB408124 (30pmol) was microinjected 
into the PVN bilaterally in a volume of 50 nl per side with a pneumatic pump 
(WPI). The approximate interval between two bilateral injections was ∼5 min. 
The volume of each injection was determined by measuring the movement of 
the fluid meniscus within the microinjector pipette using a dissecting 
microscope equipped with an eyepiece reticule. At the end of each experiment, 
26 
 
Chicago blue dye solution (2% in saline, 50 nl) was injected into the PVN to 
mark the site of each injection. Brains were removed and post fixed for 5 days 
at room temperature in 4% paraformaldehyde. Brain coronal sections 
containing the PVN were cut, and microinjection sites were identified under light 
microscopy. Rats with injection site(s) not inside the PVN were excluded from 
data analysis.  
2.10 Data analysis  
Summary data are expressed as means ± SEM. For SNA recording 
splanchnic sympathetic nerve activity (SSNA) and RSNA were determined as 
an average of the rectified, integrated signal. Baseline values of all recorded 
variables were obtained by averaging a 10-min segment of data recorded 
immediately before PVN microinjection in anesthetized rats. SSNA, RSNA, and 
MAP responses to OX1Ra SB408124 were obtained by averaging a 2-min 
period centered on the maximal response. Data are presented as percent (%) 
change from baseline after subtracting background noise determined with bolus 
injection of the ganglionic blocker hexamethonium (30 mg/kg). Both in vivo and 
in vitro data were analyzed using either a one-way anova or unpaired student t-
test. Post hoc analysis was performed with Newman-Keuls multiple comparison 
test. Differences were considered statistically significant at a critical value of P 
< 0.05. 
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Chapter 3. Results  
3.1 High Salt Diet Increases Blood Pressure in DS Rats 
In order to confirm a HS diet induces hypertension in DS but not SD rats, 
eight-week-old male adult DS rats and age and sex matched SD rats were 
placed on either a NS, 0.4% NaCl diet or HS 8% NaCl diet for 5 weeks. Blood 
pressure was monitored via telemetry transducer. SD rats on a HS diet showed 
no change in MAP compared to NS diet SD rats (HS: 108±2 vs NS: 105 ± 1 
mmHg). DS rats on a HS diet had significantly (P<0.05) increased MAP (HS: 
159 ± 6 vs. NS: 111 ± 1 mmHg) compared to NS diet DS rats (Figure 3.1).  
 
Figure 3.1 Conscious mean arterial pressure (MAP) for Sprague Dawley (SD) 
rats and Dahl salt sensitive rats (DS) after 5 weeks on a normal salt (NS; 0.4% 
NaCl) and high salt (HS; 8% NaCl) diet.  
 
3.2 High Salt Diet Increases PVN mRNA levels of Fra1, AVP, OX1R, 
and Prepro Orexin in DS Rats  
Next, we sought to determine if a HS diet alters PVN AVP and orexin 
system component expression in SD and DS rats. Eight-week-old male DS rats  
 
  
The material contained in this chapter is in preparation for submission to a journal. 
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and age and sex matched SD rats were divided into two groups and were fed 
either a NS (0.4%) or HS (8% NaCI) diet for 4-6 weeks.The rats were then 
euthanized, PVN tissue was punched out and real time PCR was performed to 
assay the chronic neuronal activation marker Fra1, AVP, prepro orexin, OX1R, 
and OX2R mRNA levels. SD rats on a HS diet showed no significant change in 
PVN mRNA levels of Fra1 (HS: 1.46±0.37 vs. NS:1.0±0.18 fold; n=4-6; P>0.05), 
OX1R (HS: 1.21±0.06 vs. NS:1.0±0.13 fold; n=4-6; P>0.05), or OX2R (HS: 
0.82±0.05 vs. NS:1.0±0.17 fold; n=4-6; P>0.05), compared to NS diet SD rats. 
SD rats on HS intake showed significantly increased PVN mRNA levels of AVP 
(HS: 1.52±0.09 vs. NS:1.0±0.09 fold; n=3-6; P<0.05), compared to NS intake 
SD rats (Figure 3.2). HS intake induced significant increases in PVN mRNA 
levels of Fra1(HS: 2.4±0.48 vs. NS:0.93±0.13; n=6; P<0.05), AVP (HS: 
2.4±0.46 vs. NS: 1.0±0.09; n=5-6; P<0.05), prepro orexin (HS: 2.5±0.46 vs. NS: 
1.0±0.28; n=7; P<0.05), and OX1R (HS: 1.5±0.09 vs. NS: 1.0±0.09; n=7; 
P<0.05) in DS rats (Figure 3.3). 
 
 
Figure 3.2 Real time PCR analysis of chronic neuronal activation marker Fra1, 
vasopressin (AVP), orexin receptor 1 (OX1R), and orexin receptor 2 (OX2R) 
mRNA expression levels in the paraventricular nucleus (PVN) between normal 
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salt (NS; 0.4% NaCl) and high salt (HS; 8% NaCl) Sprague Dawley (SD) rats. 
HS diet did not change Fra1, OX1R, or OX2R but significantly increased AVP 
PVN mRNA expression. The mRNA level in the control sample was assigned to 
be arbitrary unit (a.u) 1. *p≤0.05 vs. NS diet; n=3-6 each group. 
 
 
 
Figure 3.3 Real time PCR analysis of chronic neuronal activation marker Fra1, 
vasopressin (AVP), orexin receptor 1 (OX1R), and prepro orexin mRNA 
expression levels in the paraventricular nucleus (PVN) between normal salt 
(NS; 0.4% NaCl) and high salt (HS; 8% NaCl) Dahl salt sensitive (DS) rats. HS 
diet results in increases in mRNA levels of Fra1, AVP, OX1R, and prepro 
orexin in the PVN. The mRNA level in the control sample was assigned to be 
arbitrary unit (a.u) 1. *p≤0.05 vs. NS diet; n=5-7 each group. 
  
3.3 ICV Orexin A induces increases in PVN AVP mRNA expression 
and Orexin A Induced Increases in AVP mRNA levels are 
Attenuated by OX1R Blockade in cultured Hypothalamic 
Neurons.   
We hypothesized from the results from the above study that increased 
orexin receptor activation (OX1R or OX2R) in the PVN may be responsible for 
the enhanced PVN AVP levels in the HS intake DS rats. First In order to 
confirm orexin-A controls PVN AVP expression in vivo, male adult SD rats 
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received ICV injection of orexin-A (0.2 nmol). Three hours following injection, 
rats were euthanized and brain PVN tissues were punched out and received 
real time PCR analysis to determine AVP mRNA expression. The results 
showed that AVP mRNA levels were significantly increased 4.9-fold in orexin A 
injection rats (n=7) compared to vehicle control injected rats (P<0.05) (Figure 
3.4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4: Real time PCR analysis of paraventricular nucleus (PVN) 
vasopressin (AVP) mRNA expression levels at three hours following acute 
intracerebroventricular (ICV) infusion of vehicle control (0.9% saline) and orexin 
A (0.2 nmol) using male adult Sprague Dawley (SD) rats. The mRNA level in 
the control sample was assigned to be arbitrary unit (a.u) 1. *p≤0.05 vs. vehicle 
control; n=7. 
 
Next we determined which orexin receptor is responsible for the regulation of 
vasopressin (AVP) signaling. Primary neuronal cultures from the hypothalamus 
of new born SD rats containing the PVN were incubated with differing 
concentrations of orexin for six hours. Real time PCR was performed to assay 
mRNA levels of AVP. The results indicate that orexin treatment resulted in a 
dose dependent increase in AVP mRNA levels (100nM: 2.5-fold; 1μM; 4.8 fold; 
10μM: 15.7-fold) (n=4) (Figure 3.5 left). Next to determine the orexin receptor 
type responsible for inducing increased AVP expression, primary neuronal 
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cultures from the hypothalamus of new born SD rats were incubated with orexin 
alone or co-incubated with orexin A and the orexin receptor 1 antagonist 
(OX1Ra SB408124) or the orexin receptor 2 antagonist (OX2Ra TCS OX2 29) 
for 6 hours. Real time PCR was performed to measure AVP mRNA levels. The 
results showed that orexin (1μM) induced increases in AVP (2.7 fold) mRNA 
were attenuated by OX1Ra (1.2 fold) (P<0.05) but not OX2Ra (2.1 fold) (n=4) 
(Figure 3.5 right).  
 
Figure 3.5 Left: Incubation of primary neuronal cultures from the hypothalamus 
of new born Sprague Dawley (SD) rats containing the paraventricular nucleus 
(PVN) with increasing concentrations of orexin for six hours, the neurons were 
then collected, RNA was purified, and real time PCR was performed to assay 
mRNA levels of AVP. *p ≤0.05 vs.control; n=4 each group. Right: Incubation of 
primary neuronal cultures from the hypothalamus of new born SD rats 
containing the PVN with orexin alone or co-incubated with an orexin receptor 1 
antagonist (OX1Ra) SB408124 or orexin receptor 2 antagonist (OX2Ra) TCS 
OX2 29 for 6 hours. Real time PCR was performed to measure AVP mRNA 
levels. Orexin A induced increase in mRNA levels of vasopressin (AVP) are 
attenuated by OX1R but not OX2R blockade in hypothalamic neurons. The 
mRNA level in the control sample was assigned to be arbitrary unit (a.u) 1. *p 
≤0.05 vs.control. #p≤0.05 vs. orexin/OX1Ra. Ŧ P≤0.05 vs. orexin/OX1Ra 
treatment; n=4 each group. 
 
3.4 Acute ICV Injection of Hypertonic Saline Increases PVN OX1R 
and AVP mRNA Levels in SD rats  
The results from the above study suggest that orexin controls PVN AVP 
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expression through OX1R activation. This suggests that increased PVN OX1R 
activation, potentially via upregulation, may cause enhanced PVN AVP 
signaling in HS intake DS rats. It has been previously shown that CSF sodium 
concentration increases in DS rats on a HS diet t (64, 103). Therefore, we 
hypothesized that increased CSF sodium concentration in HS intake DS rats 
may cause PVN OX1R upregulation leading to enhanced PVN AVP signaling. It 
has previously been demonstrated that CSF sodium concentration of DS rats 
increased by 6mM after 6 days on an 8% HS diet (64). Therefore, we expect 
that after 4-6 weeks of 8% HS diet, CSF sodium concentration should increase 
by no less than 10mM. Assuming the entire CSF volume is 400 μl (142), ICV 
injection of 4 μmol NaCl should increase the CSF sodium concentration by 
10mM. Male adult SD rats received ICV injection of hypertonic saline (4 μmol) 
in order to mimic increased CSF sodium concentration of DS rats on a HS diet 
for 5 weeks as used in our study. Three hours following injection PVN tissue 
was punched, RNA was extracted and reverse transcribed to cDNA and real 
time PCR was performed to determine PVN mRNA levels of OX1R, OX2R, and 
AVP. The results showed that OX1R (1.4 fold) but not OX2R (0.97 fold) PVN 
mRNA levels were significantly increased (P<0.05) in hypertonic saline injection 
rats compared to vehicle control injection rats. AVP mRNA levels were 
significantly increased (4.8-fold) in hypertonic saline injection rats (n=5) 
compared to vehicle control injected rats (P<0.05) (Figure 3.6).  
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Figure 3.6 Real time PCR analysis of paraventricular nucleus (PVN) OX1R, 
OX2R, and vasopressin (AVP) mRNA expression levels at three hours 
following acute intracerebroventricular (ICV) infusion of vehicle control (0.9% 
saline) and hypertonic saline (4 μmol) using male adult Sprague Dawley (SD) 
rats. The mRNA level in the control sample was assigned to be arbitrary unit 
(a.u) 1. *p≤0.05 vs. vehicle control; n=4-7 each group. 
 
3.5 OX1R Blockade in PVN Reduces Blood Pressure in HS Diet DS 
Rats 
The results from the above studies indicate a HS diet increases PVN 
OX1R expression in DS rats, the OX1R mediates AVP signaling in the PVN, 
and increased CSF sodium concentration in HS intake DS rats may cause PVN 
OX1R upregulation leading to enhanced AVP signaling. Therefore, we 
hypothesized that increased OX1R activation in the PVN contributes to the 
maintenance of hypertension in HS intake DS rats. To test this hypothesis we 
recorded the MAP, SNA, and HR response to bilateral PVN microinjection of 
the OX1R antagonist SB408124 in anaesthetized DS rats fed a NS and HS diet 
for 5 weeks. OX1R antagonist SB408124 bilaterally injected into the PVN 
significantly decreased MAP in DS rats fed a HS diet compared to DS rats with 
NS intake. OX1R blockade increased SSNA and RSNA in NS and HS DS rats. 
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Figure 3.7 A-B (left panels) Shows an example of the SSNA, RSNA, and MAP 
responses to orexin receptor 1 antagonist (OX1Ra) SB408124 (30 
pmol/50nl/side) into DS rats fed a NS diet (.4%). Maximum increases in SSNA 
and RSNA were (35.82±9%; n=5) and (17.4±10%; n=6) respectively. The 
maximum decrease in MAP was (-4±4 mmHg; n=6). Figure 3.7 A-B (right 
panels) Shows an example of the SSNA, RSNA, and MAP responses to 
SB408124 (30 pmol/50nl/side) into DS rats fed a HS diet (8%). Maximum 
increases in SSNA and RSNA were greater in HS rats compared to NS rats but 
failed to reach statistical significance (HS: 48.2±12.6%; n=5 vs. NS: 35.82±9%; 
n=5, P=0.2) and (HS: 26.7±7.5%; n=5 vs. NS: 17.4±10%; n=6, P=0.2) 
respectively. The maximum decrease in MAP was greater in HS rats compared 
to NS rats (HS: -16±5 mmHg; n=5 vs. NS: -4±4 mmHg; n=6, P<0.05). Figure 
3.8 shows PVN microinjection summary data. Figure 3.9 shows a single 
representative PVN injection. It was found in four rats that dye was injected into 
the third ventricle therefore the results from these rats were not included for 
data analysis. 
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Figure 3.7 A: Representative traces showing splanchnic sympathetic nerve 
activity (SSNA), renal sympathetic nerve activity (RSNA), and mean arterial 
blood pressure (MAP) responses to bilateral PVN microinjections of Orexin 
receptor 1 antagonist (OX1Ra) SB408124 (30 pmol/50nl/side) into DS rats fed 
a normal salt diet (0.4%) left and DS rats fed a high salt diet (8%) right. B: Left 
column, 2.5-s specimen traces of SSNA (top) and RSNA (bottom) before 
injection of OX1Ra into the PVN and after microinjection of OX1Ra into the 
PVN of a DS rat on NS diet. Right column, 2.5-s specimen traces of SSNA 
(top) and RSNA (bottom) before injection of OX1Ra into the PVN and after 
microinjection of OX1Ra into the PVN of a DS rat on HS diet. PVN orexin 
receptor 1 blockade reduces blood pressure in DS rats with high salt intake. 
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Figure 3.8 Summary data showing changes in splanchnic sympathetic nerve 
activity (SSNA), renal sympathetic nerve activity (RSNA), mean arterial 
pressure (MAP), and heart rate (HR) in response to paraventricular nucleus 
(PVN) bilateral microinjections of orexin receptor 1 antagonist SB408124 (30 
pmol/50nl/side) in NS DS rats (n=5-6) and HS DS rats (n=5). *P<0.05 
compared to NS.   
 
 
 
Figure 3.9 Representation of a single injection (50nl) within the PVN. 
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Chapter 4. Discussion  
Accumulating evidence suggests that the orexin system is involved in 
the central control of cardiovascular function and its hyperactivity in the brain 
contributes to hypertension (78, 79, 81, 152), however, the role of orexin in the 
SSHTN is not known. This study is the first to investigate the contribution of the 
orexin system to SSHTN. We report six findings. First MAP is increased in DS 
rats with HS intake. Second, Fra1, AVP, OX1R, and prepro orexin mRNA 
expression are upregulated in the PVN in DS rats with HS intake. Third, ICV 
administration of orexin A increased PVN AVP mRNA expression in SD rats. 
Fourth, Incubation of cultured hypothalamic neurons from SD rats containing 
the PVN with orexin increases AVP mRNA expression which is blocked by co-
incubation with an OX1R antagonist. Fifth, ICV administration of hypertonic 
saline increase PVN OX1R and AVP mRNA levels in SD rats. Finally, PVN 
OX1R antagonist injection significantly reduces MAP in DS rats fed a HS diet 
compared to NS fed DS rats. Taken together, these findings indicate that 
increased OX1R activity in the PVN contributes to enhanced AVP signaling in 
DS rats on a HS diet which may contribute to the maintenance of Dahl SSHTN. 
The PVN is a key site for the integration of autonomic and 
neuroendocrine function, and its function is essential to maintain elevated BP in 
Dahl SSHTN (49). Expression of orexin (15, 16, 105, 113, 126, 151) and its 
receptors (5, 18, 62, 83, 89, 144) are widespread in regions of the brain 
involved in blood pressure regulation including the PVN. Our study is novel in 
that it shows that mRNA expression levels of the orexin precursor prepro orexin 
and OX1R are higher in the PVN of DS rats on a HS diet compared to DS rats 
on a NS diet (Figure 3.3). Our results also showed that DS rats on a HS diet 
had increased PVN AVP mRNA levels consistent with previous findings that 
plasma AVP is elevated in DS rats on a HS diet (90, 124, 146). We did not 
observe PVN mRNA expression of components of the orexin system in the  
 
The material contained in this chapter is in preparation for submission to a journal. 
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PVN to be changed in HS fed SD rats (Figure 3.2). These results indicate that 
a HS diet may be linked to increased PVN orexin system activity in DS rats. 
Consistent with previous studies and as expected we found that 5 weeks HS 
8% NaCl diet significantly increased MAP in DS rats but not SD rats (Figure 
3.1). 
Based on these results we hypothesized that increased PVN orexin 
system activity may be responsible for increased AVP signaling in the PVN in 
HS DS rats. First, we sought to confirm that orexin A controls PVN AVP 
expression in vivo. ICV infusion of orexin A significantly augmented PVN AVP 
mRNA expression compared to vehicle control (Figure 3.4). This is consistent 
with a previous study showing ICV injection of orexin A increased PVN AVP 
mRNA expression in conscious rats (1) and ICV administration of orexin A 
significantly increased plasma AVP levels in conscious rabbits after 90 minutes 
(91). Next, we sought to determine the receptor type orexin A may control AVP 
signaling in the PVN. We performed this study in vitro using cultured neurons 
from the hypothalamus containing the PVN from newborn SD rats. Incubation 
of cultured brain neurons with orexin A resulted in a dose dependent increase 
in AVP mRNA expression (Figure 3.5). Co-incubation with an OX1R but not 
with an OX2R antagonist attenuated this orexin induced AVP mRNA 
expression response (Figure 3.5). Taken together these results indicate that 
activation of the OX1R expressed on PVN neurons is likely responsible for 
orexin induced AVP mRNA expression. This suggest that increased PVN OX1R 
activation potentially via upregulation contributes to enhanced PVN AVP 
signaling of DS rats on a HS diet.  
DS rats on a HS diet are associated with increased CSF sodium 
concentration (64, 103) which precedes hypertension (64). It was found the 
CSF sodium concentration of DS rats but not Dahl salt resistant rats increased 
by 6mM after 6 days on an 8% HS diet preceding hypertension (64). Therefore, 
we hypothesized that increased CSF sodium concentration in HS intake DS 
rats may cause PVN OX1R upregulation leading to enhanced PVN AVP 
signaling. ICV infusion of hypertonic saline in SD rats was performed to mimic 
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an increase in CSF sodium concentration to levels observed in HS fed DS rats. 
The results showed that ICV infusion of 4 µmol NaCI significantly increased 
PVN OX1R and AVP mRNA expression (Figure 3.6) which suggests that 
increased CSF sodium concentration, a main phenotype component of DS rats 
on a HS diet, may cause PVN OX1R upregulation leading to enhanced AVP 
signaling. There have been no studies that have directly determined if orexin 
producing neurons are sensitive to changes in osmolality. It has previously 
been shown that preopro-orexin mRNA is upregulated In the hypothalamus of 
48 hour water deprived rats indicating orexin producing neurons may be 
sensitive to changes in osmolality (75). Also the lamina terminalis which is the 
location of the primary central osmoreceptors is reported to have efferent 
projections to the lateral hypothalamus where orexin producing cell bodies are 
located (58, 65) which may explain why orexin neurons would be sensitive to 
changes in body fluid osmolality. Interestingly it has been hypothesized that 
orexin neurons may be a link between the lamina terminalis sensing of 
perturbations in body fluid homeostasis and activating motivation and reward 
systems in the mesolimbic system (dopaminergic projection from the ventral 
tegmental area to the Nucleus accumbens) to effect salt and water appetite 
motivated behavior in order to restore body fluid homeostasis (65).  
Finally, since we found DS rats on HS diet displayed increased PVN 
mRNA levels of OX1R, OX1R regulates PVN AVP expression, and increased 
CSF sodium concentration in HS intake DS rats may cause PVN OX1R 
upregulation leading to enhanced AVP signaling, we determined if increased 
OX1R activation in the PVN was implicated in HS induced hypertension in DS 
rats. Microinjection of The OX1R antagonist SB408124 into the PVN elicited a 
significantly greater reduction in MAP in HS DS rats compared to NS DS rats 
(Figure 3.8). This result suggests that increased PVN OX1R activation 
contributes to the maintenance of HS induced hypertension in DS rats. This is 
likely through both increased orexin release into the PVN or increased PVN 
OX1R expression since both prepro orexin and OX1R mRNA expression were 
upregulated in the PVN of HS DS rats. PVN OX1R blockade also increased 
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both SSNA and RSNA in NS and HS rats. Since this experiment was performed 
in baroreceptor intact animals this SNA response is likely driven by the arterial 
baroreflex mechanism. It should be noted that we did not observe a parallel 
reduction in SNA along with the reduction in MAP therefore, it is plausible that 
OX1R expressed on magnocellular PVN neurons is responsible for AVP 
expression and increased OX1R activation results in greater AVP expression 
and possibly release in DS rats on HS diet contributing to the maintenance of 
hypertension. Evidence indicates orexin A may bind the OX1R and OX2R on 
presynaptic or interneuron glutamatergic PVN neurons and increases 
glutamate release to magnocellular PVN neurons (47). Also orexin A may bind 
OX1R or OX2R on magnocellular PVN neurons directly and positively 
modulates glutamate receptor activity (47). Although the contribution of AVP to 
Dahl SSHTN is still controversial, recently it was demonstrated that oral 
administration of the dual AVP receptor antagonist RWJ-676070 produced a 
transient decrease in MAP in hypertensive DS rats on a HS diet (53) 
contributing to evidence that AVP does contribute to Dahl SSHTN. However, 
we still cannot ignore the possibility that increased OX1R activation on 
parvocellular PVN neurons may be responsible for increased sympathetic tone 
and elevated BP in HS DS rats. Performing this same experiment with rats that 
have received sino-aortic denervation or severing of the baroreceptor afferents 
may clarify whether the mechanism is due to activation of OX1R on 
magnocellular or parvocellular neurons. We hypothesize that if increased OX1R 
activation on parvocellular PVN neurons is responsible for enhanced neuronal 
activity and elevated SNA contributing to hypertension of HS fed DS rats then 
OX1R blockade would result in a reduction in both SNA and MAP in sino-aortic 
denervated rats.  
4.1 Summary and Conclusion 
To summarize, the current study showed that a HS diet increased MAP 
in DS but not SD rats. DS rats on a HS diet have increased PVN mRNA 
expression of Fra1, AVP, orexin precursor, and OX1R indicating the PVN 
orexin system may be overactive in hypertensive HS DS rats which display 
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enhanced PVN AVP expression. HS intake did not alter PVN mRNA expression 
of Fra1, OX1R, or OX2R but increased PVN AVP mRNA expression in HS SD 
rats. ICV injection of orexin A in SD rats significantly increased PVN mRNA 
expression of AVP. In vitro studies showed activation of OX1R expressed on 
hypothalamic neurons mediates AVP expression. ICV infusion of hypertonic 
saline in SD rats increased PVN OX1R and AVP mRNA expression. PVN 
OX1R blockade significantly reduced MAP in DS rats on a HS diet compared to 
DS rats on a NS diet. In conclusion, these findings indicate that increased 
OX1R activity in the PVN contributes to enhanced AVP signaling in DS rats on 
a HS diet which may contribute to the maintenance of Dahl SSHTN.  
4.2 Perspectives 
Individuals with hypertension are at an increased risk for cardiovascular 
disease, the leading global cause of death. Increased dietary salt intake is a 
primary contributor to essential hypertension. Therefore, it is of great interest to 
elucidate how salt effects the blood pressure regulatory mechanisms in this salt 
sensitive population in order to further treatment possibilities to reduce the 
number of deaths caused by cardiovascular diseases. The present study 
identifies a novel mechanism were the orexin system may contribute to SSHTN 
by enhancing AVP signaling.  
4.3 Limitations and Future Studies  
There are several limitations that should be acknowledged for this study. 
First, PVN brain tissue punch for real-time PCR analysis of mRNA expression 
is not exact. Due to the small size of the PVN we acknowledge the possibility 
that other surrounding nuclei are included. Additionally, the PVN is composed 
of magnocellular AVP producing and pre sympathetic parvocellular neurons. 
Therefore, we are unable to determine whether results from real-time PCR 
analysis of mRNA expression reflect a specific neuron type. It is also important 
to note that animals used for sympathetic nerve recording experiments use an 
anaesthetized preparation. This may alter cardiovascular responses to 
microinjection of drugs used in this study (46). A major limitation in this study is 
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the use of baroreflex intact animals. The baroreflex senses and corrects acute 
changes in blood pressure through modulation of SNA. Therefore, responses to 
drugs injected into the PVN may be compensated for by reflex modulation of 
SNA making interpretation of results difficult. Future studies will include sino-
aortic denervated animals in order to remove the baroreflex response. Ongoing 
studies in our lab are examining the role of the PVN orexin system in 
augmented sympathetic outflow in the Dahl salt sensitive hypertension model.  
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Appendix A. Raw Data 
Table A.1 Raw data for Conscious Mean Arterial Blood Pressure for Sprague Dawley 
and Dahl Salt Sensitive Rats on Normal Salt and High Salt diet.  
 
MAP (mmHg) 
SD NS SD HS DSNS DS HS 
104 113 114 179 
103 110 106 173 
104 110 112 150 
105 101 113 153 
110 108 112 159 
106 107 − 140 
 
Table A.2 Raw data for PVN Fra1 mRNA Expression for Sprague Dawley Rats on 
Normal Salt and High Salt Diet. 
 
Fra1 mRNA expression normalized to GAPDH mRNA (a.u.) 
SD NS SD HS 
0.6 0.66 
0.77 2.34 
1.76 1.8 
0.61 1.02 
0.97 − 
1.25 − 
Table A.3 Raw data for PVN Arginine Vasopressin mRNA Expression for Sprague 
Dawley and Dahl Salt Sensitive Rats on Normal Salt and High Salt Diet. 
 
AVP mRNA expression normalized to GAPDH mRNA (a.u.) 
SD NS SD HS 
0.61 1.63 
1.21 1.61 
1.17 1.33 
1.18 − 
0.97 − 
0.83 − 
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Table A.4 Raw data for PVN Orexin Receptor 1 mRNA Expression for Sprague 
Dawley Rats on Normal Salt and High Salt Diet. 
 
OX1R mRNA expression normalized to GAPDH mRNA (a.u.) 
SD NS SD HS 
0.89 1.16 
1.00 1.08 
1.37 1.29 
0.72 1.45 
− 1.05 
− 1.25 
 
Table A.5 Raw data for PVN Orexin Receptor 2 mRNA Expression for Sprague 
Dawley Rats on Normal Salt and High Salt Diet. 
 
OX2R mRNA expression normalized to GAPDH mRNA (a.u.) 
SD NS SD HS 
0.75 0.68 
0.82 0.8 
1.52 0.83 
0.89 0.97 
 
Table A.6 Raw data for PVN Fra1 mRNA Expression for Dahl Salt Sensitive Rats on 
Normal Salt and High Salt Diet. 
 
Fra1 mRNA expression normalized to GAPDH mRNA (a.u.) 
DS NS DS HS 
0.40 3.13 
1.22 4.55 
0.97 2.11 
1.23 1.4 
1.13 1.54 
0.65 2.15 
 
 
Table A.7 Raw data for PVN Arginine Vasopressin mRNA Expression for Dahl Salt 
Sensitive Rats on Normal Salt and High Salt Diet. 
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AVP mRNA Expression Normalized to GAPDH mRNA (a.u.) 
DS NS DS HS 
1.12 1.89 
1.16 1.75 
0.70 4.69 
0.82 1.82 
1.17 2.09 
− 2.37 
Table A.8 Raw data for PVN Prepro Orexin mRNA Expression for Dahl Salt Sensitive 
Rats on Normal Salt and High Salt Diet. 
 
Prepro Orexin mRNA Expression Normalized to GAPDH mRNA (a.u.) 
DS NS DS HS 
2.34 3.16 
0.48 4.45 
0.16 3.76 
1.66 1.52 
0.82 1.61 
0.94 1.9 
0.56 1.42 
 
 
Table A.9 Raw data for PVN Orexin Receptor 1 mRNA Expression for Dahl Salt 
Sensitive Rats on Normal Salt and High Salt Diet. 
 
OX1R mRNA Expression Normalized to GAPDH mRNA (a.u.) 
DS NS DS HS 
0.79 1.51 
1.00 1.38 
1.20 1.21 
1.35 2.03 
0.61 1.51 
0.97 1.62 
1.05 1.41 
− 0.99 
− 0.68 
Table A.10 Raw data for PVN Arginine Vasopressin mRNA Expression Response to 
Intracerebroventricular injections of Isotonic saline and .2 nmol Orexin A in Sprague 
Dawley Rats.  
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AVP mRNA expression normalized to GAPDH mRNA (a.u.) 
Control .2 nmol Orexin A 
1.00 13.41 
1.41 4.83 
0.59 4.17 
0.71 5.98 
1.17 1.65 
1.35 2.06 
0.77 2.73 
 
Table A.11 Raw data for Arginine Vasopressin mRNA Expression Response to 10 nM, 
100 nM, 1 µM, and 10 µM Orexin treated Cultured Hypothalamic Neurons.  
 
AVP mRNA Expression Normalized to GAPDH mRNA (a.u.) 
Control 10 nM Orexin 100 nM Orexin 1 µM Orexin 10 µM Orexin 
1.37 1.76 4.12 6.25 14.22 
0.63 0.96 1.66 5.02 22.69 
0.83 1.09 2.56 2.79 8.72 
1.17 2.28 1.53 5.17 17.26 
 
 
Table A.12 Raw data for Arginine Vasopressin mRNA Expression Response to 1 µM 
Orexin, Orexin co-incubated with Orexin Receptor 1 Antagonist, Orexin co-incubated 
with Orexin Receptor 2 Antagonist treated Cultured Hypothalamic Neurons. 
 
AVP mRNA expression normalized to GAPDH mRNA (a.u.) 
Control 1 µM Orexin Orexin/OX1Ra Orexin/OX2Ra 
1.10 1.96 0.65 1.58 
0.90 2.22 1.11 2.60 
0.81 3.82 1.73 2.98 
1.19 2.98 1.32 1.56 
 
Table A.13 Raw data for PVN Orexin Receptor 1 mRNA Expression Response to 
Intracerebroventricular injections of Isotonic saline and 4µmol NaCl in Sprague 
Dawley Rats. 
OX1R mRNA expression normalized to GAPDH mRNA (a.u.) 
Control 4 µmol NaCl 
1.55 1.23 
0.45 1.53 
1.08 1.03 
0.91 1.52 
0.46 1.65 
1.23 1.37 
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1.29 1.44 
Table A.14 Raw data for PVN Orexin Receptor 2 mRNA Expression Response to 
Intracerebroventricular injections of Isotonic saline and 4µmol NaCl in Sprague 
Dawley Rats. 
 
OX2R mRNA expression normalized to GAPDH mRNA (a.u.) 
Control 4 µmol NaCl 
1.13 1.10 
0.95 0.60 
0.83 1.08 
1.08 1.11 
Table A.15 Raw data for PVN Arginine Vasopressin mRNA Expression Response to 
Intracerebroventricular injections of Isotonic saline and 4µmol NaCl in Sprague 
Dawley Rats. 
 
AVP mRNA expression normalized to GAPDH mRNA (a.u.) 
Control 4 µmol NaCl 
1.00 11.13 
1.41 5.73 
0.59 − 
0.71 1.99 
1.17 1.84 
1.35 3.57 
0.77 − 
 
Table A.16 Raw data for Splanchnic and Renal Sympathetic Nerve Activity response to 
Bilateral 30 pmol SB408124 PVN injections in Dahl Salt Sensitive Rats on Normal Salt 
diet. 
 
  
 SSNA RSNA 
 Base Max  Noise Base Max  Noise 
Rat (µV) (µV) %Change (µV) (µV) (µV) %Change (µV) 
1 0.046 0.057 37.039 0.016 0.018 0.023 45.633 0.008 
2 0.040 0.042 8.653 0.023 0.017 0.018 8.264 0.005 
3 − − − − − − − − 
4 − − − − − − − − 
5 − − − − 0.015 0.017 21.402 0.005 
6 0.022 0.027 51.236 0.013 0.009 0.008 -23.523 0.005 
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7 0.026 0.034 58.240 0.014 0.042 0.05 29.229 0.017 
8 0.022 0.025 23.907 0.010 0.028 0.031 23.859 0.017 
 
Table A.17 Raw data for Mean Arterial Pressure and Heart Rate response to Bilateral 
30 pmol SB408124 PVN injections in Dahl Salt Sensitive Rats on Normal Salt diet. 
 
   MAP     HR   
 Base 
(mmHg) 
Max 
(mmHg) 
Delta 
(mmHg) 
Base 
(mmHg) 
Max 
(mmHg) 
Delta 
(mmHg) Rat 
1 110 111 1 394 375 -19 
2 122 118 -4 363 366 3 
3 − − − − − − 
4 − − − − − − 
5 102 106 4 378 360 -18 
6 121 103 -18 385 364 -21 
7 112 118 6 416 399 -17 
8 106 95 -11 386 365 -21 
 
Table A.18 Raw data for Splanchnic and Renal Sympathetic Nerve Activity response to 
Bilateral 30 pmol SB408124 PVN injections in Dahl Salt Sensitive Rats on High Salt 
diet. 
 
 SSNA RSNA 
 Base Max  Noise Base Max  Noise 
Rat (µV) (µV) %Change (µV) (µV) (µV) %Change (µV) 
1 − − − − − − − − 
2 − − − − 0.059 0.075 36.191 0.015 
3 − − − − − − − − 
4 0.049 0.066 88.610 0.031 0.020 0.022 15.927 0.007 
5 − − − − − − − − 
6 0.041 0.048 33.406 0.019 0.021 0.024 33.322 0.012 
7 0.050 0.059 26.430 0.017 0.030 0.031 3.222 0.016 
8 0.031 0.042 66.841 0.015 0.041 0.054 45.275 0.011 
 
Table A.19 Raw data for Mean Arterial Pressure and Heart Rate response to Bilateral 30 
pmol SB408124 PVN injections in Dahl Salt Sensitive Rats on High Salt diet. 
 
   MAP     HR   
 Base 
(mmHg) 
Max 
(mmHg) 
Delta 
(mmHg) 
Base 
(mmHg) 
Max 
(mmHg) 
Delta 
(mmHg) Rat 
1 − − − − − − 
2 148 119 -29 327 326 -1 
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3 − − − − − − 
4 152 128 -24 365 342 -23 
5 − − − − − − 
6 132 128 -4 345 348 3 
7 144 133 -11 425 400 -25 
8 146 135 -11 346 321 -25 
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Appendix B. Summary Statistics 
 
Table B.1 Average Conscious Mean Arterial Blood Pressure for Sprague Dawley and 
Dahl Salt Sensitive Rats on Normal Salt and High Salt diet.   
  SD NS SD HS DS NS DS HS 
Number of values 6 6 5 6 
Mean 105.3 108.2 111.40 159.00 
Std. Deviation 2.50 4.07 3.13 14.66 
Std. Error of 
Mean 1.02 1.66 1.40 5.98 
          
Lower 95% CI of 
mean 102.7 103.9 107.5 143.6 
Upper 95% CI of 
mean 108.0 112.4 115.3 174.4 
 
Table B.2 Average PVN Fra1 mRNA Expression for Sprague Dawley and Dahl Salt 
Sensitive Rats on Normal Salt and High Salt Diet. 
  SD NS SD HS DS NS DS HS 
Number of values 6 4 6 6 
Mean 1.00 1.46 0.93 2.48 
Std. Deviation 0.44 0.75 0.33 1.18 
Std. Error of 
Mean 0.18 0.37 0.13 0.48 
          
Lower 95% CI of 
mean 0.53 0.25 0.58 1.24 
Upper 95% CI of 
mean 1.46 2.66 1.29 3.72 
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Table B.3 Average PVN Arginine Vasopressin mRNA Expression for Sprague Dawley 
and Dahl Salt Sensitive Rats on Normal Salt and High Salt Diet. 
  SD NS SD HS DS NS DS HS 
Number of values 6 3 5 6 
Mean 1.00 1.52 1.00 2.44 
Std. Deviation 0.24 0.16 0.21 1.12 
Std. Error of 
Mean 0.09 0.09 0.09 0.46 
          
Lower 95% CI of 
mean 0.74 1.1 0.73 1.25 
Upper 95% CI of 
mean 1.25 1.94 1.26 3.62 
 
Table B.4 Average PVN Prepro Orexin mRNA Expression for Dahl Salt Sensitive Rats 
on Normal Salt and High Salt Diet. 
  DS NS DS HS 
Number of values 7 7 
Mean 1.00 2.52 
Std. Deviation 0.75 1.23 
Std. Error of 
Mean 0.28 0.46 
      
Lower 95% CI of 
mean 0.29 1.41 
Upper 95% CI of 
mean 1.70 3.69 
Table B.5 Average PVN Orexin Receptor 1 mRNA Expression for Sprague Dawley 
and Dahl Salt Sensitive Rats on Normal Salt and High Salt Diet. 
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  SD NS SD HS DS NS DS HS 
Number of values 4 6 7 7 
Mean 1.00 1.21 1.00 1.52 
Std. Deviation 0.27 0.14 0.24 0.25 
Std. Error of 
Mean 0.13 0.06 0.09 0.09 
          
Lower 95% CI of 
mean 0.56 1.06 0.77 1.29 
Upper 95% CI of 
mean 1.43 1.37 1.22 1.76 
 
Table B.6 Average PVN Orexin Receptor 2 mRNA Expression for Sprague Dawley 
Rats on Normal Salt and High Salt Diet. 
  SD NS SD HS 
Number of values 4 6 
Mean 1.00 0.82 
Std. Deviation 0.35 0.13 
Std. Error of 
Mean 0.17 0.05 
      
Lower 95% CI of 
mean 0.44 0.68 
Upper 95% CI of 
mean 1.55 0.97 
 
 
Table B.7 Average PVN Arginine Vasopressin mRNA Expression Response to 
Intracerebroventricular injections of Isotonic saline and .2 nmol Orexin A in Sprague 
Dawley Rats. 
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  Control .2 nmol Orexin A 
Number of values 7 7 
Mean 1.00 4.97 
Std. Deviation 0.32 4.02 
Std. Error of 
Mean 0.12 1.52 
      
Lower 95% CI of 
mean 0.70 1.24 
Upper 95% CI of 
mean 1.29 8.70 
Table B.8 Average Arginine Vasopressin mRNA Expression Response to 10 nM, 100 
nM, 1 µM, and 10 µM Orexin A treated Cultured Hypothalamic Neurons. 
  Control 10 nM Orexin 
100 nM 
Orexin 
1 µM 
Orexin 
10 µM 
Orexin 
Number of values 4 4 4 4 4 
Mean 1.00 1.52 2.46 4.80 15.72 
Std. Deviation 0.33 0.61 1.19 1.45 5.83 
Std. Error of 
Mean 0.16 0.30 0.59 0.72 2.91 
            
Lower 95% CI of 
mean 0.47 0.54 0.56 2.49 6.43 
Upper 95% CI of 
mean 1.52 2.5 4.36 7.11 25.01 
 
Table B.9 Average Arginine Vasopressin mRNA Expression Response to 1 µM Orexin, 
Orexin co-incubated with Orexin Receptor 1 Antagonist, Orexin co-incubated with 
Orexin Receptor 2 Antagonist 
  Control 1 µM Orexin 
Orexin/ 
OX1Ra 
Orexin/ 
OX2Ra 
Number of values 4 4 4 4 
Mean 1.00 2.74 1.20 2.18 
Std. Deviation 0.17 0.83 0.44 0.72 
Std. Error of 
Mean 0.08 0.41 0.22 0.36 
          
Lower 95% CI of 
mean 0.72 1.41 0.48 1.03 
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Upper 95% CI of 
mean 1.27 4.07 1.91 3.32 
 
Table B.10 Average PVN Orexin Receptor 1 mRNA Expression Response to 
Intracerebroventricular injections of Isotonic saline and 4µmol NaCl in Sprague 
Dawley Rats. 
 
  Control 4 µmol NaCl 
Number of values 7 7 
Mean 1.00 1.40 
Std. Deviation 0.41 0.21 
Std. Error of 
Mean 0.15 0.07 
      
Lower 95% CI of 
mean 0.61 1.20 
Upper 95% CI of 
mean 1.38 1.59 
 
Table B.11 Average PVN Orexin Receptor 2 mRNA Expression Response to 
Intracerebroventricular injections of Isotonic saline and 4µmol NaCl in Sprague 
Dawley Rats. 
 
  Control 4 µmol NaCl 
Number of values 4 4 
Mean 1.00 0.97 
Std. Deviation 0.13 0.25 
Std. Error of 
Mean 0.06 0.12 
      
Lower 95% CI of 
mean 0.78 0.57 
Upper 95% CI of 
mean 1.21 1.37 
Table B.12 Average PVN Arginine Vasopressin mRNA Expression Response to 
Intracerebroventricular injections of Isotonic saline and 4µmol NaCl in Sprague 
Dawley Rats. 
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  Control 4 µmol NaCl 
Number of values 7 5 
Mean 1.00 4.85 
Std. Deviation 0.32 3.84 
Std. Error of 
Mean 0.12 1.71 
      
Lower 95% CI of 
mean 0.70 0.08 
Upper 95% CI of 
mean 1.29 9.62 
 
Table B.13 Mean splanchnic sympathetic nerve activity % change from baseline 
following PVN microinjection of OX1R antagonist SB408124 in Normal Salt and High 
Salt Dahl Salt Sensitive rats. 
  SB408124 DS NS 
SB408124 
DS HS 
Number of 
values 5 5 
Mean 35.82 48.20 
Std. Deviation 20.14 28.19 
Std. Error of 
Mean 9.00 12.61 
      
Lower 95% CI 
of mean 10.81 13.19 
Upper 95% CI 
of mean 60.82 83.21 
 
Table B.14 Mean renal sympathetic nerve activity % change from baseline following 
PVN microinjection of OX1R antagonist SB408124 in Normal Salt and High Salt Dahl 
Salt Sensitive rats. 
  SB408124 DS NS 
SB408124 
DS HS 
Number of 
values 6 5 
Mean 17.48 26.79 
Std. Deviation 23.46 16.93 
Std. Error of 
Mean 9.57 7.57 
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Lower 95% CI 
of mean -7.14 5.76 
Upper 95% CI 
of mean 42.10 47.81 
Table B.15 Mean change from baseline for mean arterial pressure (mmHg) following 
PVN microinjection of OX1R antagonist SB408124 in Normal Salt and High Salt Dahl 
Salt Sensitive rats. 
  SB408124 DS NS 
SB408124 
DS HS 
Number of 
values 6 5 
Mean -3.66 -15.80 
Std. Deviation 9.30 10.33 
Std. Error of 
Mean 3.80 4.62 
      
Lower 95% CI 
of mean -13.44 -28.63 
Upper 95% CI 
of mean 6.10 -2.97 
Table B.16 Mean change from baseline for heart rate (beats/minute) following PVN 
microinjection of OX1R antagonist SB408124 in Normal Salt and High Salt Dahl Salt 
Sensitive rats. 
  SB408124 DS NS 
SB408124 
DS HS 
Number of 
values 6 5 
Mean -15.50 -14.20 
Std. Deviation 9.20 13.97 
Std. Error of 
Mean 3.75 6.24 
      
Lower 95% CI 
of mean -25.16 -31.55 
Upper 95% CI 
of mean -5.84 3.14 
Table B.17 Unpaired t-test comparing MAP and PVN mRNA expression of Fra1, 
Arginine Vasopressin, Orexin Receptor 1, and Orexin Receptor 2 between Normal Salt 
and High Salt Sprague Dawley rats. 
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  Fra1 mRNA 
AVP 
mRNA 
OX1R 
mRNA 
OX2R 
mRNA MAP 
Group 1  SD NS  SD NS  SD NS  SD NS SD NS 
vs. vs vs vs vs vs 
Group 2 SD HS SD HS SD HS SD HS SD HS 
      
Unpaired t test     
P value 0.2573 0.0121 0.1411 0.3033 0.177 
P value summary ns * ns ns ns 
One- or two-tailed P 
value? 
Two-
tailed 
Two-
tailed 
Two-
tailed 
Two-
tailed 
Two-
tailed 
t, df t=1.220  df=8 
t=3.357 
df=7 
t=1.633 
df=8 
t=1.100 
df=8 
t=1.452 
df=10 
 
Table B.18 Unpaired t-test comparing MAP PVN mRNA expression of Fra1, Arginine 
Vasopressin, Prepro Orexin, and Orexin Receptor 1 between Normal Salt and High Salt 
Dahl Salt Sensitive Rats. 
  Fra1 mRNA 
AVP 
mRNA 
Prepro 
Orexin 
mRNA 
OX1R 
mRNA MAP 
Group 1  DS NS DS NS DS NS DS NS DS NS 
vs. vs vs vs vs vs 
Group 2 DS HS DS HS DS HS DS HS DS HS 
      
Unpaired t test     
P value 0.0117 0.0210 0.0148 0.0019 <0.0001 
P value summary * * * ** **** 
One- or two-tailed P 
value? 
Two-
tailed 
Two-
tailed 
Two-
tailed 
Two-
tailed 
Two-
tailed 
t, df t=3.077 df=10 
t=2.791 
df=9 
t=2.842 
df=12 
t=3.959 
df=12 
t=7.068 
df=9 
 
 
Table B.19 Unpaired t-test comparing PVN Arginine Vasopressin mRNA Expression 
Response to Intracerebroventricular injections of control vs. 2 nmol Orexin A in 
Sprague Dawley Rats. 
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  AVP mRNA 
Group 1 Control 
vs. vs 
Group 2 .2 nmol Orexin A 
    
Unpaired t test   
P value 0.0232 
P value summary * 
One- or two-tailed P 
value? Two-tailed 
t, df t=2.602 df=12 
 
Table B.20 Unpaired t-test comparing Arginine Vasopressin mRNA Expression 
Response to Control vs. 10nM orexin, 100 nM orexin, 1 µM Orexin, and 10 µM Orexin 
treatment in cultured hypothalamic neurons. 
  AVP mRNA 
AVP 
mRNA 
AVP 
mRNA 
AVP 
mRNA 
Group 1 Control Control Control Control 
vs. vs vs vs vs 
Group 2 10 nM Orexin 
100 nM 
Orexin 
1 µM 
Orexin 
10 µM 
Orexin 
    
Unpaired t test   
P value 0.1855 0.0555 0.0022 0.0024 
P value summary ns ns ** ** 
One- or two-tailed P 
value? 
Two-
tailed 
Two-
tailed 
Two-
tailed 
Two-
tailed 
t, df t=1.495 df=6 
t=2.370 
df=6 
t=5.111 
df=6 
t=5.037 
df=6 
 
 
Table B.21 One way anova with post hoc Newman-Keuls test comparing Arginine 
Vasopressin mRNA Expression Response between control, 1 µM Orexin, Orexin co-
incubated with Orexin Receptor 1 Antagonist, Orexin co-incubated with Orexin 
Receptor 2 Antagonist treated hypothalamic neurons. 
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ANOVA summary    
F 7.458   
P value 0.0044   
R square 0.6509   
    
ANOVA table SS DF MS 
Treatment (between 
columns) 8.132 3 2.711 
Residual (within 
columns) 4.362 12 0.3635 
Total 12.49 15  
    
Newman-Keuls Mean Diff. Significant ? Summary 
Control vs 1 µM 
Orexin -1.745 Yes ** 
Control vs Orexin/ 
OX2Ra -1.18 Yes * 
Control vs Orexin/ 
OX1Ra -0.202 No ns 
Orexin/OX1Ra vs 1 
µM Orexin -1.543 Yes ** 
Orexin/OX1Ra vs 
Orexin/OX2Ra -0.977 Yes * 
Orexin/OX2Ra vs 1 
µM Orexin -0.565 No ns 
Table B.22 Unpaired t-test comparing Orexin Receptor 1, Orexin Receptor 2, and Arginine 
Vasopressin mRNA response between intracerebroventricular injections of isotonic saline 
vs. 4 µmol NaCl in Sprague Dawley rats. 
 
  OX1R mRNA 
OX2R 
mRNA AVP mRNA 
Group 1 Control Control  Control 
vs. vs vs vs 
Group 2 4 µmol NaCl 4 µmol NaCl 4 µmol NaCl 
        
Unpaired t test       
P value 0.0433 0.87 0.0226 
P value summary * ns * 
One- or two-tailed P 
value? Two-tailed Two-tailed Two-tailed 
t, df t=2.259 df=12 t=0.1663, df=6 t=2.694 df=10 
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Table B.23 Unpaired t-test comparing splanchnic sympathetic nerve activity % change, 
renal sympathetic nerve activity % change, mean arterial pressure, and heart rate change 
from baseline following PVN microinjection of OX1R antagonist SB408124 in Normal 
Salt and High Salt Dahl Salt Sensitive rats. 
  SSNA RSNA MAP HR 
Group 1 SB408124 DS NS 
SB408124 
DS NS 
SB408124 
DS NS 
SB408124 
DS NS 
vs. vs vs vs vs 
Group 2 SB408124 DS HS 
SB408124 
DS HS 
SB408124 
DS HS 
SB408124 
DS HS 
          
Unpaired t test         
P value 0.2236 0.2395 0.0353 0.4284 
P value summary ns ns * ns 
One- or two-
tailed P value? One-tailed One-tailed One-tailed One-tailed 
t, df t=0.7992 df=8 
t=0.7387 
df=9 
t=2.050 
df=9 
t=0.1856 
df=9 
 
